San Diego, CA -- (SBWIRE) -- 03/17/2021 -- An investor, who purchased NASDAQ: AQST shares , filed a lawsuit over alleged violations of Federal Securities Laws by Aquestive Therapeutics, Inc..

Investors who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and for certain investors are short and strict deadlines running. Deadline: April 30, 2021. NASDAQ: AQST investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Warren, NJ based Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. On December 2, 2019, Aquestive Therapeutics, Inc. announced the completion of the rolling submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for Libervant Buccal Film for the management of seizure clusters (the "Libervant NDA").

On September 25, 2020, Aquestive Therapeutics, Inc. announced receipt of a Complete Response Letter ("CRL") from the FDA indicating that the review cycle for the Libervant NDA was complete but the application could not be approved in its current form. Specifically, Aquestive Therapeutics, Inc. advised investors that "[i]n the CRL, the FDA cited that, in a study submitted by the Company with the NDA, certain weight groups showed a lower drug exposure level than desired. The Company intends to provide to the FDA additional information on PK modeling to demonstrate that dose adjustments will obtain the desired exposure levels."

Shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) declined from $9.46 per share on September 11, 2020, to as low as $4.38 per share on October 2, 2020.

The plaintiff claims that between December 2, 2019 and September 25, 2020, the Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that data included in the Libervant NDA submission showed a lower drug exposure level than desired for certain weight groups, that the foregoing significantly decreased the Libervant NDA's approval prospects, that as a result, it was foreseeable that the FDA would not approve the Libervant NDA in its current form, and that as a result, the Company's public statements were materially false and misleading at all relevant times.

Those who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.